NEW YORK (GenomeWeb) – Cancer researchers at Ohio State University are using a $1.4 million grant from the National Cancer Institute to develop a next-generation sequencing-based test that can determine microsatellite instability across a range of tumors and help guide patients to precision medicine trials.
The OSU team, led by Sameek Roychowdhury, developed an MSI-calling software called MANTIS, which they will use as part of the test to identify the hypermutational characteristic in tumors. The researchers plan to add the MSI detection capabilities to a 280-gene NGS panel that OSU’s cancer center offers to patients.
“Next-generation sequencing is going to be a great way to expand MSI testing in cancer because today patients are all undergoing NGS for advanced cancers,” Roychowdhury said. “It doesn’t make sense to have them undergo so many different tests when it can all be bundled into the same assay. Especially with a finite specimen, you can’t afford to keep doing multiple tests.”
OSU’s NGS panel currently detects single-nucleotide variants, indels, and copy number variations, and is intended to help doctors identify potential on- or off-label personalized treatment options for patients, as well as clinical trials that patients might join based on their tumor markers. Roychowdhury’s